Free Access
Med Sci (Paris)
Volume 20, Number 1, Janvier 2004
Page(s) 45 - 53
Section M/S revues
Published online 15 January 2004
  1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346 : 561–4. [Google Scholar]
  2. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258 : 1946–9. [Google Scholar]
  3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 : 61–5. [Google Scholar]
  4. Fride E. Endocannabinoids in the central nervous system-an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 221–33. [Google Scholar]
  5. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in the brain that bind to the cannabinoid receptor. J Med Chem 1993; 36 : 3032–4. [Google Scholar]
  6. Mechoulam R, Ben-Shabat S, Hanus L, et al. identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 : 83–90. [Google Scholar]
  7. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98 : 3662–5. [Google Scholar]
  8. Giuffrida R, Beltramo M, Piomelli D. Mechanism of endocannabinoid inactivation : biochemistry and pharmacology. J Pharm Exp Ther 2001; 298 : 7–14. [Google Scholar]
  9. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 101–21. [Google Scholar]
  10. Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C. In cultured mouse astrocytes, but not in neurons, anandamide has pharmacological effects distincts from synthetic cannabinoids. Eur J Neurosci 1999; 11 : 691–9. [Google Scholar]
  11. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptors on anxiety. Eur J Neurosci 2002; 16 : 395–8. [Google Scholar]
  12. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 377–91. [Google Scholar]
  13. Suguira T, Koyabashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 173–92. [Google Scholar]
  14. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58 : 315–48. [Google Scholar]
  15. McAllister SD, Glass M. CB1 and CB2 receptor-mediated signalling : a focus on endocannabinoids. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 161–71. [Google Scholar]
  16. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo J 2001; 20 : 7033–40. [Google Scholar]
  17. Maingret F, Patel AJ, Lazdunski M, Honore E. The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. Embo J 2001; 20 : 47–54. [Google Scholar]
  18. Schweitzer P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 2000; 20 : 51–8. [Google Scholar]
  19. Venance L, Piomelli D, Glowinski J, Giaume C. Inhibition by anadamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 1995; 376 : 590–4. [Google Scholar]
  20. Venance L, Sagan S, Giaume C. R-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes. Eur J Physiol 1997; 434 : 147–9. [Google Scholar]
  21. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids : involvement of sustained ceramide accumulation and extracellular signal-regulated kinase regulation. Nat Med 2000; 6 : 313–9. [Google Scholar]
  22. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95 : 175–84. [Google Scholar]
  23. Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 2002; 5 : 723–4. [Google Scholar]
  24. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296 : 678–82. [Google Scholar]
  25. Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 2002; 12 : 324–30. [Google Scholar]
  26. Llano I, Leresche N, Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 1991; 6 : 565–74. [Google Scholar]
  27. Pitler TA, Alger BE. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 1992; 12 : 4122–32. [Google Scholar]
  28. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001; 21 : 109–16. [Google Scholar]
  29. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99 : 8384–8. [Google Scholar]
  30. Doherty J, Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 2003; 3 : 46–53. [Google Scholar]
  31. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 2002; 5 : 446–51. [Google Scholar]
  32. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418 : 530–4. [Google Scholar]
  33. Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999; 10 : 327–31. [Google Scholar]
  34. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38 : 151–78. [Google Scholar]
  35. Ledent C, Valverde O, Cossu G, et al. Unresponsivenes to cannabinoids and feduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283 : 15. [Google Scholar]
  36. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63 : 569–611. [Google Scholar]
  37. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998; 286 : 1301–8. [Google Scholar]
  38. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 : 277–281. [Google Scholar]
  39. Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 1999; 19 : 6795–805. [Google Scholar]
  40. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388 : 773–8. [Google Scholar]
  41. Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999; 379 : R1-R2 [Google Scholar]
  42. Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res 1998; 812 : 270–4. [Google Scholar]
  43. Chakrabarti A, Ekuta JE, Onaivi ES. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Res Bull 1998; 45 : 67–74 [Google Scholar]
  44. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology 2002; 163 : 111–7. [Google Scholar]
  45. Miczek KA. Delta9-tetrahydrocannabinol : Antiagressive effects in mice, rats, and squirrel monkeys. Science 1978; 199 : 1459–61. [Google Scholar]
  46. Rodriguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414 : 209–12. [Google Scholar]
  47. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95 : 127–35. [Google Scholar]
  48. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353 : 560. [Google Scholar]
  49. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95 : 203–20. [Google Scholar]
  50. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95 : 185–90. [Google Scholar]
  51. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21 : 218–24. [Google Scholar]
  52. Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002; 95 : 137–52. [Google Scholar]
  53. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95 : 165–74. [Google Scholar]
  54. Van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002; 26 : 317–46. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.